Clinical Trial Update: Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease [Phase 1, Phase 2]

View source ↗

Summary

The document reports completion of a Phase 1/2 safety study evaluating a pegylated interferon variant (PEG-IFN-SA) for hepatitis C infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• PEG-IFN-SA (pegylated interferon-alpha)

Snippet

Sponsor: The First Hospital of Jilin University | Conditions: Hepatitis C Virus | Phase 1, Phase 2 | Status: COMPLETED